Discovery and Characterization of Olokizumab: A Humanized Antibody Targeting Interleukin-6 and Neutralizing Gp130-Signaling

DOI: 10.4161/mabs.28612
PMID: 24670876

Authors: Stevan Shaw (UCB Pharma; Berkshire) , Tim Bourne (UCB Pharma; Berkshire) , Chris Meier (UCB Pharma; Berkshire) , Bruce Carrington (UCB Pharma; Berkshire) , Rich Gelinas (UCB Pharma; Berkshire) , Alistair Henry (UCB Pharma; Berkshire) , Andrew Popplewell (UCB Pharma; Berkshire) , Ralph Adams (UCB Pharma; Berkshire) , Terry Baker (UCB Pharma; Berkshire) , Steve Rapecki (UCB Pharma; Berkshire) , Diane Marshall (UCB Pharma; Berkshire) , Adrian Moore (UCB Pharma; Berkshire) , Helen Neale (UCB Pharma; Berkshire) , Alastair Lawson (UCB Pharma; Berkshire)
Co-authored by industrial partner: Yes

Type: Journal Paper
Journal: Mabs , VOL 6 , PAGES 773 - 781

State: Published (Approved)
Published: April 2014

Abstract: Interleukin-6 (IL-6) is a critical regulator of the immune system and has been widely implicated in autoimmune disease. Here, we describe the discovery and characterization of olokizumab, a humanized antibody to IL-6. Data from structural biology, cell biology and primate pharmacology demonstrate the therapeutic potential of targeting IL-6 at “Site 3”, blocking the interaction with the signaling co-receptor gp130.

Journal Keywords: Interleukin 6; Il-6; Antibody; Site 3;

Subject Areas: Biology and Bio-materials


Instruments: I02-Macromolecular Crystallography

Added On: 18/11/2015 14:32

Discipline Tags:



Technical Tags: